Menarcheal age influences bone micro-architecture at peak bone mass in healthy women

compared to a 6% reduction with placebo (p=0.003). Risedronate increased spine bone mineral content by 45% in the treatment group compared to 19% in patients receiving placebo (p=0.02). In contrast, peripheral quantitative computed tomography did not show any treatment differences at either radial metaphysis or diaphysis. Histomorphometric analysis of transiliac bone biopsies at the end of the study period did not reveal a significant treatment difference in cortical width, trabecular bone volume or parameters of bone turnover. Similarly, there was no detectable treatment effect on vertebral morphometry, second metacarpal cortical width, grip force, bone pain, or number of new fractures. Regarding safety, risedronate was generally well tolerated and the incidence of clinical or laboratory adverse experiences was similar among treatment groups. In summary, oral risedronate treatment for 2 years in pediatric patients with mild OI increased spine bone mineral content and was generally well tolerated.